Worth reading
45Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Avoiding a definitive answer
How definitive the wording is.Agreements reached under this partnership
Business alliance4586Medrx Co.,Ltd.
Alliance partnerTerrain Pharmaceuticals
Details of the alliance
- 1
U.S. sales partnership for Bondlido
- 2
Signing of a sales license agreement
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
About the partner
Business DescriptionDevelopment and sale of topical analgesics. Through a nationwide distribution network comprising independent retail pharmacies, specialty pharmacies and healthcare institutions, the company markets prescription and over-the-counter topical patches and semisolid formulations, including products based on lidocaine and NSAIDs.
LocationReno, Nevada, U.S.
Impact on Business Performance
The impact on the current fiscal year's earnings forecast is currently under review. The company will promptly disclose the impact on earnings once it is determined.
Contract DateMay 2026
| Item | Details |
|---|---|
| Name of alliance partner | Terrain Pharmaceuticals |
| Alliance partner's business activities | Development and sale of topical analgesics. Through a nationwide distribution network comprising independent retail pharmacies, specialty pharmacies and healthcare institutions, the company markets prescription and over-the-counter topical patches and semisolid formulations, including products based on lidocaine and NSAIDs. |
| Alliance partner's location | Reno, Nevada, U.S. |
| Type of alliance | Business alliance |
| Details of the alliance | U.S. sales partnership for Bondlido, Signing of a sales license agreement |
| Contract Date | May 2026 |
| Impact on Business Performance | The impact on the current fiscal year's earnings forecast is currently under review. The company will promptly disclose the impact on earnings once it is determined. |
Items this document does not state (16)
Alliance partner's capitalAlliance partner's net salesAlliance partner's operating incomeNumber of shares acquiredAcquisition priceShareholding ratioOverview of the joint ventureOwnership ratioDispatch of directors and officersContract PeriodNumerical targets under the allianceShareholding PolicyDate of board resolutionAlliance start dateShare Acquisition Date and Payment DateChange in major shareholders
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Projected sales volumes over the next several years are expected to exceed the assumptions made when the contractual terms were agreed, and reviewing the sales strategy, supply plan and contract terms is taking time.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.